methyl 1-(4-fluorobenzyl)-4-(trifluoromethylsulfonyloxy)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate | 868551-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: methyl 1-(4-fluorobenzyl)-4-(trifluoromethylsulfonyloxy)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate
• 英文别名: methyl 1-(4-fluorobenzyl)-4-{[(trifluoromethyl)sulfonyl]oxy}-1H-pyrrolo[2,3-c]pyridine-5-carboxylate；1h-Pyrrolo[2,3-c]pyridine-5-carboxylic acid,1-[(4-fluorophenyl)methyl]-4-[[(trifluoromethyl)sulfonyl]oxy]-,methyl ester；methyl 1-[(4-fluorophenyl)methyl]-4-(trifluoromethylsulfonyloxy)pyrrolo[2,3-c]pyridine-5-carboxylate
• CAS: 868551-52-4
• 化学式: C₁₇H₁₂F₄N₂O₅S
• 分子量: 432.352
• InChiKey: OXOGZPNQCBKUHO-UHFFFAOYSA-N

物化性质

• 沸点：
  574.5±50.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  95.9
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  methyl 1-(4-fluorobenzyl)-4-(trifluoromethylsulfonyloxy)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate 在 tris-(dibenzylideneacetone)dipalladium(0) 、 N-甲基二环己基胺 、 sodium cyanoborohydride 、 对甲苯磺酸 、 溶剂黄146 、 N,N-二异丙基乙胺 、 氯甲酸苯酯 、 lithium chloride 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 105.0h， 生成 1-[[(tetrahydro-2H-pyran-4-yl)methoxy]methyl]-3-(4-fluorobenzyl)-7-{[2-(trimethylsilyl)ethoxy]methoxy}-3,7,8,9-tetrahydro-6H-pyrrolo-[2,3-c][1,7]naphthyridin-6-one
  参考文献：
  名称：

  Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors

  摘要：

  HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.

  DOI：

  10.1021/jm200208d
• 作为产物：
  描述：

  2-甲基吡咯-3-甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 palladium 10% on activated carbon 、 potassium tert-butylate 、 氢气 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， -78.0~20.0 ℃ 、275.8 kPa 条件下， 反应 42.5h， 生成 methyl 1-(4-fluorobenzyl)-4-(trifluoromethylsulfonyloxy)-1H-pyrrolo[2,3-c]pyridine-5-carboxylate
  参考文献：
  名称：

  Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors

  摘要：

  HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.

  DOI：

  10.1021/jm200208d

文献信息

• INHIBITORS OF THE HIV INTEGRASE ENZYME
  申请人：Dress Ruprecht Klaus

  公开号：US20070099915A1

  公开（公告）日：2007-05-03

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.

  本发明涉及式（I）的化合物，以及其在药学上可接受的盐和溶剂化合物，它们的合成，以及它们作为人类免疫缺陷病毒（“HIV”）整合酶的调节剂或抑制剂的用途。
• [EN] INHIBITORS OF THE HIV INTEGRASE ENZYME<br/>[FR] INHIBITEURS DE L'ENZYME INTEGRASE DU VIH
  申请人：PFIZER

  公开号：WO2005103051A1

  公开（公告）日：2005-11-03

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.

  本发明涉及化合物的公式（I），以及其药用可接受的盐和溶剂，它们的合成，以及它们作为人类免疫缺陷病毒（“HIV”）整合酶的调节剂或抑制剂的用途。
• Discovery of an HIV integrase inhibitor with an excellent resistance profile
  作者：David C. Pryde、Rob Webster、Scott L. Butler、Edward J. Murray、Kevin Whitby、Chris Pickford、Mike Westby、Michael J. Palmer、David J. Bull、Hannah Vuong、David C. Blakemore、Darren Stead、Christopher Ashcroft、Iain Gardner、Claire Bru、Wai-Yee Cheung、Ieuan O. Roberts、Jennifer Morton、Richard A. Bissell

  DOI：10.1039/c3md00014a

  日期：——

  In the present article, we describe SAR studies within a series of N-hydroxy-dihydronaphthyridinone HIV integrase inhibitors that led to a candidate compound, PF-4776548, of high potency and with an excellent resistance profile. Uncertainties around the human pharmacokinetic predictions for PF-4776548 led to the compound being taken into a human microdose study to confirm its human pharmacokinetics, the results of which are described herein.

  在本文中，我们介绍了一系列 N-hydroxy-dihydronaphridthyinone HIV 整合酶抑制剂的 SAR 研究，该研究产生了一个候选化合物 PF-4776548，它具有很高的效力和出色的耐药性。由于 PF-4776548 的人体药代动力学预测存在不确定性，因此该化合物被纳入了一项人体微剂量研究，以确认其人体药代动力学，研究结果将在本文中介绍。
• Inhibitors of the HIV integrase enzyme
  申请人：Dress Ruprecht Klaus

  公开号：US20050277661A1

  公开（公告）日：2005-12-15

  The present invention is directed to compounds of formula (i), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.

  本发明涉及式（i）的化合物及其药学上可接受的盐和溶剂，它们的合成，以及它们作为人类免疫缺陷病毒（“HIV”）整合酶酶的调节剂或抑制剂的用途。
• [EN] PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS DE L'ENZYME INTEGRASE DU VIH
  申请人：PFIZER

  公开号：WO2005103003A3

  公开（公告）日：2006-03-16